- Home
- NXTC vs IBO Comparison
NXTC vs IBO Comparison
Compare NXTC & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- IBO
- Stock Information
- Founded
- NXTC 2015
- IBO 2018
- Country
- NXTC United States
- IBO United States
- Employees
- NXTC N/A
- IBO N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- IBO
- Sector
- NXTC Health Care
- IBO
- Exchange
- NXTC Nasdaq
- IBO NYSE
- Market Cap
- NXTC 20.6M
- IBO 22.1M
- IPO Year
- NXTC 2019
- IBO 2024
- Fundamental
- Price
- NXTC $0.40
- IBO $0.57
- Analyst Decision
- NXTC Strong Buy
- IBO
- Analyst Count
- NXTC 2
- IBO 0
- Target Price
- NXTC $3.50
- IBO N/A
- AVG Volume (30 Days)
- NXTC 99.1K
- IBO 10.7M
- Earning Date
- NXTC 03-06-2025
- IBO 05-23-2025
- Dividend Yield
- NXTC N/A
- IBO N/A
- EPS Growth
- NXTC N/A
- IBO N/A
- EPS
- NXTC N/A
- IBO N/A
- Revenue
- NXTC N/A
- IBO N/A
- Revenue This Year
- NXTC N/A
- IBO N/A
- Revenue Next Year
- NXTC N/A
- IBO N/A
- P/E Ratio
- NXTC N/A
- IBO N/A
- Revenue Growth
- NXTC N/A
- IBO N/A
- 52 Week Low
- NXTC $0.35
- IBO $0.51
- 52 Week High
- NXTC $2.49
- IBO $6.17
- Technical
- Relative Strength Index (RSI)
- NXTC 22.20
- IBO N/A
- Support Level
- NXTC $0.49
- IBO N/A
- Resistance Level
- NXTC $0.67
- IBO N/A
- Average True Range (ATR)
- NXTC 0.09
- IBO 0.00
- MACD
- NXTC -0.02
- IBO 0.00
- Stochastic Oscillator
- NXTC 12.74
- IBO 0.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.